A cross talk between adropin and possible metabolic syndrome disorders in experimental male albino rats

Mayada Mohamed Ahmed Azab; Nermen Mohamed Mady; Enas Mohamed El Bendary; Sahar Ahmed El Sawy

doi:10.53730/ijhs.v6nS4.10904

Authors

Mayada Mohamed Ahmed Azab
mayada.azab@med.tanta.edu.eg
Physiology Department, Faculty of Medicine, Tanta University, Egypt
Nermen Mohamed Mady Physiology Department, Faculty of Medicine, Tanta University, Egypt
Enas Mohamed El Bendary Physiology Department, Faculty of Medicine, Tanta University, Egypt
Sahar Ahmed El Sawy Physiology Department, Faculty of Medicine, Tanta University, Egypt

Keywords:

adropin, metabolic syndrome, streptozotocin, diabetes, PPARα

Abstract

This research is to study the relationship between adropin and possible metabolic syndrome disorders, also to assess the role of PPAR-α in these disorders in rats. 50 male rats were divided into 5 groups: I-Control group, II-Obese group, III-Obese diabetic group, IV-Adropin treated obese group, V-Adropin treated obese diabetic group. At the end, body weight, BMI, AC/TC ratio and lee index was measured, blood samples were collected for measuring glucose , insulin, HbA1C , HOMA-IR , HOMA-β , TC, TG, HDL-C , LDL-C, atherogenic index , ALT, AST & GGT. The liver was dissected for measuring PPARα expression, TNF-α, IL6 & iNOS. High fat diet produced a significant increase in all anthropometric measures in group (II) and (III) compared to control group. After adropin administration they were signiﬁcantly decreased. The serum blood glucose, insulin, HbA1c and HOMA-IR were significantly increased, while Β- cell function significantly decreased in group (II) and (III) compared to control, however after adropin administration they showed significant decrease while, HOMA-β was significantly decreased. Group (II) and (III) showed significant lipid profile deterioration compared to control group, after adropin treatment lipid profile was significantly improved.

Downloads

Download data is not yet available.

References

Akcilar R., Kocak F., Simsek H., Akcilar A., Bayat Z., Ece E., et al. (2016): Antidiabetic and hypolipidemic effects of adropin in streoptozotocin-induced type-2 diabetic rats. Bratislavske Lekarske Listy; 117(2): 100–105.

Akrabawi S and Salji J. (1973): Influence of meal-feeding on some of the effects of dietary carbohydrate deficiency in rats. Br. J. Nutr; 30(1): 37–43.

Angeloco L., Deminice R., Leme I., Lataro R., and Jordao A. (2012): Bioelectrical impedance analysis and anthropometry for the determination of body composition in rats: effects of high-fat and high-sucrose diets. Rev. Nutr; 25(3): 331-339.

Artwohl J., Brown P., Corning B and Stein S. (2006): Report of the ACLAM task force on rodent euthanasia. J Am Assoc Lab Anim Sci; 45(1): 98-105.

Assmann G., Jabs H., Kohnert U., Nolte W. and Schriewer H. (1984): LDL-cholesterol determination in blood serum following precipitation of LDL with polyvmylsulfate. Clin Chim Acta; 140(7): 77-83.

Berger J., Leibowitz M., Doebber T., Elbrecht A., Zhang B., Zhou G., et al. (1999): Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARα ligands produce distinct biological effects. J Biol Chem; 274(10): 6718–6725.

Blanc M., Rhie F., Dunn J and Soeldner J. (1981): The determination of glycosylated hemoglobin in rats using high pressure liquid chromatography. Metabolism; 30(4): 317-322.

Carvalho V., Barreto E., Arantes A., Serra M., Ferreira T., Jannini-Sa Y., et al. (2018): Diabetes downregulates allergen‐induced airway inflammation in mice. Mediators Inflamm; 13(5): 6150843.

Cave M., Clair H., Hardesty J., Falkner K., Feng W., Clark B., et al. (2016): Nuclear receptors and nonalcoholic fatty liver disease. Biochim Biophys Acta; 1859(9): 1083–1099.

Chang J., Chu N., Lin F., Hsu J and Chen P. (2018): Relationship between plasma adropin levels and body composition and lipid characteristics amongst young adolescents in Taiwan. Obes Res Clin Pract; 12(2):101-107.

Cheng H; Yaw H; Ton S; Choy S; Kong J and Abdul Kadir K. (2016): Glycyrrhizic acid prevents high calorie diet-induced metabolic aberrations despite the suppression of peroxisome proliferator-activated receptor γ expression. Nutrition; 7(1): 61-75.

Chevenne D., Ruiz J., Lohmann L., Laudat A., Leblanc H., Gray P., et al. (1994): Immuno-radiometric assay of human intact pro-insulin applied to patients with type-2 diabetes, impaired glucose tolerance, and hyperandrogenism. Clin Chem; 40(5): 754-757.

Costa D., Huckestein B., Edmunds L., Petersen M., Nasiri A., Butrico G., et al. (2016): Reduced intestinal lipid absorption and body weight-independent improvements in insulin sensitivity in high-fat diet-fed Park2 knockout mice. Am. J. Physiol. Endocrinol. Metab; 311(1): 105–116.

Dang S., Leng Y., Wang Z., Xiao X., Zhang X., Wen T., et al. (2019): Exosomal transfer of obesity adipose tissue for decreased miR-141-3 p mediates insulin resistance of hepatocytes. Int. J. Biol. Sci; 15(2): 351–368.

Dawson T., Bredt D., Fotuhi M., Hwang P., and Snyder S. (1991): Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc Natl Acad Sci USA; 88(17): 7797-7798.

Ding M., Si D., Zhang W., Feng Z., He M and Yang P. (2014): Red yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia. Exp Ther Med; 8(6):1737-1744.

Dobiasova M. (2004): Atherogenic Index of Plasma [log (triglyceride/HDL-Cholesterol)]: Theoretical and Practical Implications. Clin. Chem; 50(7): 1113–1115.

Galicia-Garcia U., Jebari S., Larrea-Sebal A., Uribe K.B., Siddiqi H., Ostolaza H., et al. (2020): Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. Int. J. Mol. Sc; 21(13): 4725.

Ganesh Kumar K., Zhang J., Gao S., Rossi J., McGuinness O., Halem H., et al. (2012): Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring); 20(7):1394–1402.

Gao S., McMillan R., Zhu Q., Lopaschuk G., Hulver M and Butler A. (2015): Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet induced obese mice with insulin resistance. Mol Metab; 17(4): 310-324.

Gharibi S., Tabatabaei B., Saeidi G and Goli S. (2016): Effect of drought stress on total phenolic, lipid peroxidation, and antioxidant activity of Achillea species. Appl Biochem Biotechnol; 178(4): 796–809.

Grove T. (1979): Effect of reagent pH on determination of high-density lipoprotein cholesterol by precipitation with sodium phosphotungstate-magnesium. Clin. Chem; 25(4): 560-564.

Haas J., Francque S and Staels B. (2016): Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. Annu Rev Physiol; 78(1): 181-205.

Haffner S., Kennedy E., Gonzalez C., Stern MP., and Iettinen H. (1996): A prospective analysis of the HOMA model: the Mexico City Diabetes Study. Diabetes Care; 19(10): 1138–1141.

Huang X., Choi Y., Im H., Yarimaga O., Yoon E and Kim H. (2006): Aspartate aminotransferase (AST/GOT) and Alanine aminotransferase (ALT/GPT) detection techniques. Sensors; 6(7): 756–782.

Ivanova E., Myasoedova V., Melnichenko A., and Orekhov A. (2017): “Peroxisome proliferator-activated receptor (PPAR) gamma agonists as therapeutic agents for cardiovascular disorders: focus on atherosclerosis”. Current Pharmaceutical Design; 23(7): 1119–1124.

Jacas J., Gao S., McMillan R., Zhu Q., Li X., Kumar G., et al. (2014): Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes; 63(10): 3242-3252.

Jung U and Choi M. (2014): “Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inﬂammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease,” International Journal of Molecular Sciences; 15(4): 6184– 6223.

Kataoka T., Hotta Y., Maeda Y and Kimura K. (2014): Assessment of androgen replacement therapy for erectile function in rats with type 2 diabetes mellitus by examining nitric oxide-related and inﬂammatory factors. J Sex Med; 11(4): 920–929.

Kitade H., Chen G., Ni Y and Ota T. (2017): Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients; 9(4): 387.

Kocaoglu C., Buyukinan M., Erdem S., and Ozel A. (2015): Are obesity and metabolic syndrome associated with plasma adropin levels in children. Journal of Pediatric Endocrinology and Metabolism; 28(2): 1293-1297.

Kuloglu T and Aydin S. (2014): Immuno-histochemical expressions of adropin and inducible nitric oxide synthase in renal tissues of rats with streptozotocin induced experimental diabetes. Biotech Histochem; 89(2): 104-110.

Kunkel S., Elmore C., Bongers K., Ebert S., Fox D., Dyle M., et al. (2012): Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS One; 7(6): 3933-3935.

Kurtieva, S. (2021). Adaptation capabilities of functional systems of the body of adolescents with vegetative dystonia syndrome. International Journal of Health & Medical Sciences, 4(1), 129-135. https://doi.org/10.31295/ijhms.v4n1.1622

Lovren F., Pan Y., Quan A., Singh K., Shukla PC., Gupta M., et al. (2010): Adropin is a novel regulator of endothelial function. Circulation; 14(11): 185-192.

Matthews D., Hosker J., Rudenski A., Naylor B., Treacher D., and Turner R. (1985): Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia; 28(7): 412–419.

Mc Gowan M., Artiss J., Standbergh D., Strandbergh D., and Zak B. (1983): Peroxidase-coupled method for colorimetric determination of serum triglycerides. Clin. Chem; 29(3): 538-542.

Miao H., Chen H., Pei S., Bai X., Vaziri N and Zhao Y. (2015): Plasma lipidomics reveal profound perturbation of glycerophospholipids, fatty acids, and sphingolipids in diet-induced hyperlipidemia. Chem Biol Interact; 228(25): 79-87.

Mirtschink P., Jang C., Arany Z and Krek W. (2018): Fructose metabolism, cardio-metabolic risk, and the epidemic of coronary artery disease. Eur. Heart J; 39(26): 2497–2505.

Muoio D. (2014): Metabolic inflexibility: when mitochondrial indecision leads to metabolic gridlock. Cell; 159(6): 1253–1262.

Nascimento A., Sugizaki M., Leopoldo A., Lima-lLeopoldo A., Luvizotto R., Nogueira C., et al. (2008): A hypercaloric pellet-diet cycle induces obesity and co-morbidities in wistar rats. Arquivos Brasileeiros de Endocrinologia & Metabologia; 52(6): 968-974.

Novelli E., Diniz Y., Galhardi C., Ebaid G., Mani F and Novelli V. (2007): Anthropometrical parameters and markers of obesity in rats. Laboratory animals; 41(1): 111-119.

Oruc C., Akpinar Y., Dervisoglu E., Amikishiyev S., Salmaslıoglu A., Gurdol F., et al. (2017): Low concentrations of adropin are associated with endothelial dysfunction as assessed by ﬂow-mediated dilatation in patients with metabolic syndrome. Clin. Chem. Lab. Med; 55(1): 139–144.

Partridge C., Fawcett G., Wang B., Semenkovich C and Cheverud J. (2014): The effect of dietary fat intake on hepatic gene expression in LG/J and SM/J mice. BMC Genomics; 15: 99.

Pawlak M., Lefebvre P and Staels B. (2015): Molecular mechanism of PPAR-alpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol; 62(3): 720–733.

Sato K., Yamashita R., Shirai K., Shibata T., Okano M., Yamaguchi., et al. (2018): Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int. J. Mol. Sci; 19(5):1293.

Sawada M., Kondo N., Suzumura A., and Marunouchi T. (1989): Production of tumor necrosis factor-α by microglia and astrocytes in culture. Brain Res; 491(2): 394–397.

Sharif S., Hariri R., Chang V., Barie P., Wang R., and Ghajar B. (1993): Human astrocyte production of tumor necrosis factor-α, interleukin-1β and interleukin-6 following exposure to lipopolysaccharide endotoxin. Neurol Res; 15(12): 109–112.

Shiferaw W., Akalu T., Gedefaw M., Aynalem Y., Anthony D., Mengesha A., et al. (2020): Metabolic syndrome among Type-2 Diabetes Patients in Sub-Saharan African countries: a systematic review and meta-analysis. PLoS One; 15(11): e0241432.

Srinivasan K., Viswanad B., Lydia A and Ramarao P. (2005): Combination of high-fat diet fed and low-dose streptozotocin-treated rat: A model for type-2 diabetes and pharmacological screening. Pharm Res; 52(4): 313–320.

Stein L., Yosten G and Samson W. (2016): Adropin acts in brain to inhibit water drinking: potential interaction with the orphan G protein-coupled receptor, GPR19. Am. J. Physiol. Regul. Integr. Comp. Physiol; 310(6): 476–480.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Thapa B and Anuj W. (2007): Liver Function Tests and their Interpretation. Indian J Pediatr; 74(7): 663671-663672.

Thapa D., Stoner M., Zhang M., Xie B., Manning J., Guimaraes D., et al. (2019): Adropin treatment restores cardiac glucose oxidation in pre-diabetic obese mice. J. Mol. Cell. Cardiol; 129(1):174–178.

Tian J., Wu F., Yang C., Jiang M., Liu W and Wen H. (2015): Dietary lipid levels impact lipoprotein lipase, hormone-sensitive lipase, and fatty acid synthetase gene expression in three tissues of adult GIFT strain of Nile tilapia, Oreochromis niloticus. Fish Physiology and Biochemistry; 41(1): 1-18.

Tietz N. (1986): Determination of blood glucose, Text book of clinical chemistry WB Saunders. Co. London, Philadelphia; 796.

Wang W., Zhang H., Gao G., Baı Q., Lı R and Wang X. (2011): Adiponectin Inhibits Hyperlipidemia-Induced Platelet Aggregation via Attenuating Oxidative/Nitrative Stress. Physiol Res; 60(3): 347-354.

Wasilewska N., Bobrus-Chociej A., Harasim-Symbor E., Tarasow E., Wojtkowska M., Chabowski A., et al. (2018): Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease. Lipids Health Dis; 17(1): 216.

Zheng Q., Wang J., Zhou H., Niu S., Liu Q., Yang Z., et al. (2017): Effectiveness of Amygdalus mongolica oil in hyperlipidemic rats and underlying antioxidant processes. J Toxicol Environ Health A; 80(22): 1193–1198.